Vaccination With PD-L1 Peptide With Montanide Against Multiple Myeloma After High Dose Chemotherapy With Stem Cell Support. A Phase I First-in-human Study.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2018
At a glance
- Drugs IO-103 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- 30 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Apr 2018 New trial record